$NVMI

Waisman Gabriel sold $513K of NVMI

Waisman Gabriel (CEO & President) sold 1,500 shares of NOVA LTD. (NVMI) at $342.27 ($0.51M total) on 2026-09-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Waisman Gabriel
Published Sep 2, 2026, 8:25 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 2, 2026, 9:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NVMI
Bearish
medium confidence
Mentioned
$NVMI
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NVMIBearishLow
01

Why it matters

The disclosed sale may lead to short-term price pressure but likely limited given the small size relative to total holdings.

02

Market read

Primary insider sale news for NVMI; modest trading relevance.

03

What to watch

The CEO retains a sizable stake, and the sale represents less than 1% of total shares.

Relevance 4/10Novelty 4/10Timing: filing date Sep 2, 2026

Background

Form 4 filing discloses insider transactions required by SEC, providing transparency on executive holdings.

Company-level read

Ticker impact

$NVMIBearishMedium confidence
Context

CEO Gabriel sold 1,500 shares for $513K via a 10b5-1 plan, reducing his stake to 27,214 shares.

Expected impact

possible modest dip of 1-2% in the near term

Evidence & confidence

Sale size is modest relative to holdings but involves the CEO; market may view it as a negative signal.

Market effects

Minimal impact on the broader sector; only relevant to NVMI investors.

None

None

Counterpoint

The sale could be routine under a pre-arranged plan, not indicative of future performance.

Key entities

  • Waisman Gabriel

    CEO & President of Nova Ltd.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NVMIMedAI 8/10

Nova (NVMI) Just Blew Past $250M In Quarterly Sales

Nova (NVMI) reported Q2 2026 revenue of $255M, up 8% QoQ and 16% YoY, with GAAP net income of $75M and non-GAAP net income of $86.5M. GAAP EPS was $2.20, up from $2.04 QoQ and $2.14 YoY. Non-GAAP EPS was $2.51, up from $2.33 QoQ and $2.20 YoY. The company guided Q3 2026 revenue to $277M-$287M, GAAP EPS to $2.46-$2.61, and non-GAAP EPS to $2.70-$2.85. Gross margin declined to 56.5% from 57.7% QoQ and 57.8% YoY.

$ESLTMed

Tue: Rate cut lifts market

The Tel Aviv Stock Exchange rose after the Bank of Israel cut interest rates to 3.25%. The Tel Aviv 35 Index gained 0.22%, while Dimri led gains with a 5.47% rise. OPC Energy fell 4.67%, the biggest decline. Key movers included Elbit Systems, Teva, and Ormat, which rose, and Camtek and Tower Semiconductor, which fell.

$NVMIHigh

NOVA LTD. (NVMI): Financial results for Q2 2026

NOVA LTD. (NVMI) furnished an SEC Form 6-K — earnings release. Attached hereto and incorporated by way of reference herein is a press release issued by the Registrant and entitled: “Nova Reports Record Second Quarter 2026 Financial Results”. The GAAP financial statements tables included in the press release attached hereto are hereby incorpo

$TEVAMed

Wed: Teva jumps but TASE continues to lose ground

Globes reports the Tel Aviv Stock Exchange fell on July 29, with the Tel Aviv 35 down 0.99% and Tel Aviv 125 down 0.96%. Teva Pharmaceutical (NYSE: TEVA; TASE: TEVA) rose 10.17% after Q2 results and raised revenue guidance. Other movers included Enlight Renewable Energy, Elbit Systems, and banks such as Bank Leumi and Hapoalim.